Omeros (NASDAQ:OMER) & Viemed Healthcare (NASDAQ:VMD) Head-To-Head Contrast

Viemed Healthcare (NASDAQ:VMD) and Omeros (NASDAQ:OMER) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their risk, valuation, earnings, dividends, institutional ownership, profitability and analyst recommendations.

Profitability

This table compares Viemed Healthcare and Omeros’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Viemed Healthcare	5.34%	9.95%	7.34%
Omeros	N/A	N/A	-55.49%

Risk and Volatility

Viemed Healthcare has a beta of 1.29, indicating that its share price is 29% more volatile than the S&P 500. Comparatively, Omeros has a beta of 2.4, indicating that its share price is 140% more volatile than the S&P 500.

Insider & Institutional Ownership

74.2% of Viemed Healthcare shares are held by institutional investors. Comparatively, 48.8% of Omeros shares are held by institutional investors. 20.0% of Viemed Healthcare shares are held by company insiders. Comparatively, 12.9% of Omeros shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current ratings for Viemed Healthcare and Omeros, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Viemed Healthcare	0	1	0	0	2.00
Omeros	1	1	2	1	2.60

Omeros has a consensus price target of $33.67, suggesting a potential upside of 244.95%. Given Omeros’ stronger consensus rating and higher probable upside, analysts plainly believe Omeros is more favorable than Viemed Healthcare.

Valuation & Earnings

This table compares Viemed Healthcare and Omeros”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Viemed Healthcare	$224.26 million	1.17	$11.27 million	$0.33	20.91
Omeros	N/A	N/A	-$156.82 million	($2.02)	-4.83

Viemed Healthcare has higher revenue and earnings than Omeros. Omeros is trading at a lower price-to-earnings ratio than Viemed Healthcare, indicating that it is currently the more affordable of the two stocks.

Summary

Viemed Healthcare beats Omeros on 9 of the 14 factors compared between the two stocks.

About Viemed Healthcare

Viemed Healthcare, Inc., together with its subsidiaries, provides home medical equipment (HME) and post-acute respiratory healthcare services to patients in the United States. It provides respiratory disease management solutions, including treatment of chronic obstructive pulmonary disease (COPD), which include non-invasive ventilation, percussion vests, and other therapies; and invasive and non-invasive ventilation and related equipment and supplies to patients suffering from COPD. The company leases non-invasive and invasive ventilators, positive airway pressure machines (PAP), durable medical equipment, percussion vests, oxygen concentrators, and other medical equipment; and sells and rents HME devices. In addition, it provides neuromuscular care and oxygen therapy services; and sleep apnea management provides sleep solutions and/or equipment, such as PAP, automatic continuous positive airway pressure, and bi-level positive airway pressure machines. Further, the company offers in home sleep apnea testing services, as well as healthcare staffing and recruitment services. Viemed Healthcare, Inc. was founded in 2006 and is headquartered in Lafayette, Louisiana.

About Omeros

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19. It also develops OMS1029 that is in phase I clinical trials for long-acting second-generation antibody targeting lectin pathway disorders; OMS906 that has completed phase II clinical trials for Paroxysmal nocturnal hemoglobinuria, complement 3 glomerulopathy, and other alternative pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders. In addition, the company’s products under preclinical development comprise MASP-2, a pro-inflammatory protein target for the treatment of lectin pathway disorders; MASP-3 small-molecule inhibitors for alternative pathway disorders; and Adoptive T-Cell and Chimeric Antigen Receptor (CAR) T-Cell Therapies and Immunomodulators/Immunotoxins/Cancer Vaccines for the treatment of various cancers. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.